A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
RecruitingOBSERVATIONAL
Enrollment
80
Participants
Timeline
Start Date
January 10, 2022
Primary Completion Date
January 10, 2025
Study Completion Date
January 10, 2026
Conditions
Multiple MyelomaMinimal Residual Disease
Trial Locations (1)
130021
RECRUITING
The First Hospital of Jilin University, Changchun
All Listed Sponsors
lead
FengYan Jin
OTHER
NCT06109233 - A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment | Biotech Hunter | Biotech Hunter